These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1461581)

  • 41. What's new: proton pump inhibitors and pediatrics.
    Patel AS; Pohl JF; Easley DJ
    Pediatr Rev; 2003 Jan; 24(1):12-5. PubMed ID: 12509540
    [No Abstract]   [Full Text] [Related]  

  • 42. Omeprazole.
    Langman MJ
    BMJ; 1991 Aug; 303(6801):481-2. PubMed ID: 1680515
    [No Abstract]   [Full Text] [Related]  

  • 43. Omeprazole. Overview and opinion.
    Holt S; Howden CW
    Dig Dis Sci; 1991 Apr; 36(4):385-93. PubMed ID: 2007354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Recent developments in drugs antagonistic to factors causing peptic ulcer--clinical efficacy and problems; gastric mucosa proton pump inhibitors].
    Okabe S; Akimoto Y
    Nihon Rinsho; 1988 Jan; 46(1):33-8. PubMed ID: 2836641
    [No Abstract]   [Full Text] [Related]  

  • 45. Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.
    Tack J; Louis E; Persy V; Urbain D
    Acta Gastroenterol Belg; 2013 Dec; 76(4):393-402. PubMed ID: 24592542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Silent acid reflux and asthma control.
    Asano K; Suzuki H
    N Engl J Med; 2009 Apr; 360(15):1551-3. PubMed ID: 19357411
    [No Abstract]   [Full Text] [Related]  

  • 47. [Optimal use of proton pump inhibitors in primary care].
    Tack J; Louis E; Persy V; Urbain D
    Rev Med Liege; 2014 Mar; 69(3):139-45. PubMed ID: 24830213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
    Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
    J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular mechanisms in therapy of acid-related diseases.
    Shin JM; Vagin O; Munson K; Kidd M; Modlin IM; Sachs G
    Cell Mol Life Sci; 2008 Jan; 65(2):264-81. PubMed ID: 17928953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Over 30 Years of Omeprazole.
    Sharma P
    J Assoc Physicians India; 2023 Aug; 71(8):11-12. PubMed ID: 37651247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fine structural and morphometric studies on gastric parietal cells of peptic ulcer patients after long-term treatment with omeprazole.
    Kobayashi H; Watanabe T; Nakahara A; Mutoh H; Tanaka N; Uchiyama Y
    Arch Histol Cytol; 1998 Oct; 61(4):287-95. PubMed ID: 9862143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacology of omeprazole.
    Howden CW
    Clin Pharmacokinet; 1991 Jan; 20(1):38-49. PubMed ID: 2029801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastroesophageal reflux disease and asthma: the role of proton pump inhibitors.
    Menon MS; Al-Hajji M; Morice A
    Chest; 2006 Jun; 129(6):1732; author reply 1732-3. PubMed ID: 16778299
    [No Abstract]   [Full Text] [Related]  

  • 54. Omeprazole failure in a patient with gastroesophageal reflux disease.
    Just R; Katzka DA; Castell DO
    Ann Intern Med; 1994 Dec; 121(11):899. PubMed ID: 7978711
    [No Abstract]   [Full Text] [Related]  

  • 55. Omeprazole, the first proton pump inhibitor for peptic ulcer disease. Proceedings of the symposium held during the 8th Asian Pacific Congress of Gastroenterology. Seoul, Korea, 11 October 1988.
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():1-81. PubMed ID: 2491357
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of an oral suspension containing xyloglucan and pea proteins on a murine model of gastroesophageal reflux disease.
    Ardizzone A; Mannino D; Casili G; Campolo M; Paterniti I; Lanza M; Filippone A; Repici A; Bova V; Capra AP; Cuzzocrea S; Esposito E
    Phytother Res; 2024 Mar; 38(3):1610-1622. PubMed ID: 38296262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of gastric acid in gastric ulcer formation in rabbits with antibody-induced prostaglandin deficiency.
    Lee M; Aldred K; Lee E; Prince MD; Feldman M
    Gastroenterology; 1992 Nov; 103(5):1467-74. PubMed ID: 1426865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is gastric acid hypersecretion the only reason for refractory gastroesophageal reflux disease?
    Savarino V; Mela GS; Zentilin P; Celle G
    Gastroenterology; 1990 Nov; 99(5):1542-3. PubMed ID: 2210269
    [No Abstract]   [Full Text] [Related]  

  • 59. [Advances in the knowledge of peptic-acid dependent diseases].
    Mazure PA; Pigliacampo J
    Acta Gastroenterol Latinoam; 1989; 19(3):165-73. PubMed ID: 2576850
    [No Abstract]   [Full Text] [Related]  

  • 60. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.
    Wolfe MM; Sachs G
    Gastroenterology; 2000 Feb; 118(2 Suppl 1):S9-31. PubMed ID: 10868896
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.